Stem definition | Drug id | CAS RN |
---|---|---|
monoamine oxydase (MAO)-inhibitors type B | 2429 | 14611-51-9 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.89 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 4.40 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.90 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.13 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.30 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 5, 1989 | FDA | SOMERSET |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site rash | 181.48 | 27.41 | 35 | 1661 | 2388 | 56287983 |
Application site erythema | 170.27 | 27.41 | 37 | 1659 | 4563 | 56285808 |
Application site pruritus | 99.12 | 27.41 | 23 | 1673 | 3796 | 56286575 |
Application site reaction | 90.52 | 27.41 | 16 | 1680 | 670 | 56289701 |
Dyskinesia | 80.67 | 27.41 | 31 | 1665 | 29077 | 56261294 |
Application site urticaria | 75.97 | 27.41 | 12 | 1684 | 250 | 56290121 |
Hallucination | 74.34 | 27.41 | 34 | 1662 | 49115 | 56241256 |
Hallucination, visual | 68.37 | 27.41 | 24 | 1672 | 17444 | 56272927 |
Parkinsonism hyperpyrexia syndrome | 67.96 | 27.41 | 10 | 1686 | 127 | 56290244 |
Application site irritation | 59.45 | 27.41 | 13 | 1683 | 1639 | 56288732 |
Drug interaction | 36.79 | 27.41 | 38 | 1658 | 209717 | 56080654 |
Application site pain | 30.14 | 27.41 | 9 | 1687 | 3911 | 56286460 |
Impulse-control disorder | 27.74 | 27.41 | 6 | 1690 | 717 | 56289654 |
Delusion | 27.68 | 27.41 | 11 | 1685 | 11204 | 56279167 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hallucination | 161.72 | 29.13 | 76 | 2341 | 46334 | 31648593 |
Dyskinesia | 127.83 | 29.13 | 51 | 2366 | 20859 | 31674068 |
Hallucination, visual | 87.77 | 29.13 | 36 | 2381 | 15758 | 31679169 |
Impulse-control disorder | 86.69 | 29.13 | 20 | 2397 | 1256 | 31693671 |
Hypersexuality | 84.59 | 29.13 | 20 | 2397 | 1398 | 31693529 |
Gambling disorder | 77.09 | 29.13 | 19 | 2398 | 1583 | 31693344 |
Dopamine dysregulation syndrome | 73.90 | 29.13 | 14 | 2403 | 332 | 31694595 |
Application site rash | 68.14 | 29.13 | 15 | 2402 | 761 | 31694166 |
On and off phenomenon | 67.14 | 29.13 | 18 | 2399 | 2092 | 31692835 |
Delusion | 62.07 | 29.13 | 26 | 2391 | 11971 | 31682956 |
Application site erythema | 44.18 | 29.13 | 13 | 2404 | 2116 | 31692811 |
Parkinsonism hyperpyrexia syndrome | 41.67 | 29.13 | 7 | 2410 | 81 | 31694846 |
Binge eating | 32.74 | 29.13 | 6 | 2411 | 118 | 31694809 |
Impulsive behaviour | 31.94 | 29.13 | 10 | 2407 | 2003 | 31692924 |
Orthostatic hypotension | 29.64 | 29.13 | 20 | 2397 | 24099 | 31670828 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hallucination | 179.90 | 24.75 | 83 | 3354 | 76177 | 70848830 |
Application site rash | 165.36 | 24.75 | 34 | 3403 | 1975 | 70923032 |
Dyskinesia | 164.17 | 24.75 | 65 | 3372 | 41009 | 70883998 |
Hallucination, visual | 151.58 | 24.75 | 56 | 3381 | 29281 | 70895726 |
Application site erythema | 131.17 | 24.75 | 33 | 3404 | 4728 | 70920279 |
Parkinsonism hyperpyrexia syndrome | 107.59 | 24.75 | 17 | 3420 | 214 | 70924793 |
Impulse-control disorder | 101.35 | 24.75 | 22 | 3415 | 1657 | 70923350 |
Gambling disorder | 87.38 | 24.75 | 20 | 3417 | 1918 | 70923089 |
Hypersexuality | 86.10 | 24.75 | 19 | 3418 | 1544 | 70923463 |
Dopamine dysregulation syndrome | 75.37 | 24.75 | 14 | 3423 | 476 | 70924531 |
Delusion | 75.31 | 24.75 | 30 | 3407 | 19135 | 70905872 |
Application site pruritus | 61.06 | 24.75 | 17 | 3420 | 3584 | 70921423 |
Application site urticaria | 50.74 | 24.75 | 9 | 3428 | 235 | 70924772 |
Application site irritation | 43.48 | 24.75 | 11 | 3426 | 1606 | 70923401 |
Parkinson's disease | 42.34 | 24.75 | 11 | 3426 | 1784 | 70923223 |
On and off phenomenon | 42.00 | 24.75 | 12 | 3425 | 2774 | 70922233 |
Muscle rigidity | 36.80 | 24.75 | 18 | 3419 | 18632 | 70906375 |
Application site reaction | 35.49 | 24.75 | 8 | 3429 | 715 | 70924292 |
Orthostatic hypotension | 35.07 | 24.75 | 25 | 3412 | 51718 | 70873289 |
Drug interaction | 31.80 | 24.75 | 62 | 3375 | 381379 | 70543628 |
Sudden onset of sleep | 31.12 | 24.75 | 7 | 3430 | 620 | 70924387 |
Insomnia | 30.98 | 24.75 | 45 | 3392 | 217761 | 70707246 |
Psychotic disorder | 29.74 | 24.75 | 20 | 3417 | 37681 | 70887326 |
Sleep talking | 27.59 | 24.75 | 7 | 3430 | 1034 | 70923973 |
Binge eating | 27.26 | 24.75 | 6 | 3431 | 481 | 70924526 |
Tremor | 26.38 | 24.75 | 35 | 3402 | 155589 | 70769418 |
Choking | 25.86 | 24.75 | 12 | 3425 | 11048 | 70913959 |
Agitation | 25.83 | 24.75 | 27 | 3410 | 93348 | 70831659 |
Marital problem | 25.68 | 24.75 | 5 | 3432 | 219 | 70924788 |
Application site pain | 24.91 | 24.75 | 9 | 3428 | 4393 | 70920614 |
Impulsive behaviour | 24.89 | 24.75 | 8 | 3429 | 2746 | 70922261 |
Pneumonia aspiration | 24.77 | 24.75 | 22 | 3415 | 62267 | 70862740 |
None
Source | Code | Description |
---|---|---|
ATC | N04BD01 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Monoamine oxidase B inhibitors |
FDA MoA | N0000000184 | Monoamine Oxidase Inhibitors |
MeSH PA | D018726 | Anti-Dyskinesia Agents |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D000978 | Antiparkinson Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D008996 | Monoamine Oxidase Inhibitors |
MeSH PA | D018696 | Neuroprotective Agents |
MeSH PA | D020011 | Protective Agents |
MeSH PA | D011619 | Psychotropic Drugs |
CHEBI has role | CHEBI:176497 | geroprotectors |
CHEBI has role | CHEBI:38623 | monoamine oxidase inhibitors |
CHEBI has role | CHEBI:48407 | antiparkinson agent |
CHEBI has role | CHEBI:48560 | dopaminergic agents |
FDA EPC | N0000175744 | Monoamine Oxidase Inhibitor |
FDA MoA | N0000175761 | Monoamine Oxidase-B Inhibitors |
FDA EPC | N0000175762 | Monoamine Oxidase Type B Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Parkinson's disease | indication | 49049000 | DOID:14330 |
Major depressive disorder | indication | 370143000 | |
Suicidal thoughts | contraindication | 6471006 | |
Bipolar disorder | contraindication | 13746004 | DOID:3312 |
Orthostatic hypotension | contraindication | 28651003 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Psychotic disorder | contraindication | 69322001 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Tardive dyskinesia | contraindication | 102449007 | |
Angina pectoris | contraindication | 194828000 | |
Mania | contraindication | 231494001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pheochromocytoma | contraindication | 302835009 | |
Malignant melanoma | contraindication | 372244006 |
Species | Use | Relation |
---|---|---|
Dogs | Cognitive dysfunction syndrome (CDS) | Indication |
Dogs | Pituitary dependent hyperadrenocorticism (PDH) | Indication |
Product | Applicant | Ingredients |
---|---|---|
Anipryl | Zoetis Inc. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.6 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Amine oxidase [flavin-containing] B | Enzyme | INHIBITOR | Ki | 7.26 | CHEMBL | CHEMBL | |||
Alpha-2B adrenergic receptor | GPCR | Ki | 6.76 | DRUG MATRIX | |||||
Amine oxidase [flavin-containing] A | Enzyme | Ki | 5.04 | CHEMBL | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.17 | DRUG MATRIX | |||||
Alpha-synuclein | Transporter | IC50 | 6.57 | CHEMBL | |||||
Amine oxidase [flavin-containing] B | Enzyme | Ki | 5.87 | CHEMBL | |||||
Amine oxidase [flavin-containing] A | Enzyme | Ki | 4.98 | CHEMBL | |||||
Amine oxidase [flavin-containing] A | Enzyme | Ki | 5.42 | CHEMBL | |||||
Amine oxidase [flavin-containing] B | Enzyme | Ki | 6.01 | CHEMBL | |||||
Monoamine oxidase | Enzyme | IC50 | 7.89 | CHEMBL |
ID | Source |
---|---|
4019929 | VUID |
N0000148014 | NUI |
D00785 | KEGG_DRUG |
14611-52-0 | SECONDARY_CAS_RN |
4019485 | VANDF |
4019929 | VANDF |
C0036579 | UMLSCUI |
CHEBI:50217 | CHEBI |
CHEMBL972 | ChEMBL_ID |
DB01037 | DRUGBANK_ID |
CHEMBL1200904 | ChEMBL_ID |
D012642 | MESH_DESCRIPTOR_UI |
26757 | PUBCHEM_CID |
4436 | INN_ID |
6639 | IUPHAR_LIGAND_ID |
2K1V7GP655 | UNII |
203137 | RXNORM |
1551 | MMSL |
21238 | MMSL |
53269 | MMSL |
5448 | MMSL |
63129 | MMSL |
d00976 | MMSL |
003465 | NDDF |
004599 | NDDF |
108466000 | SNOMEDCT_US |
108467009 | SNOMEDCT_US |
372497003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
ZELAPAR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0453 | TABLET, ORALLY DISINTEGRATING | 1.25 mg | ORAL | NDA | 25 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-737 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
Selegiline Hydrochloride | Human Prescription Drug Label | 1 | 16571-659 | CAPSULE | 5 mg | ORAL | ANDA | 19 sections |
EMSAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49502-900 | PATCH | 6 mg | TRANSDERMAL | NDA | 31 sections |
EMSAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49502-901 | PATCH | 9 mg | TRANSDERMAL | NDA | 31 sections |
EMSAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49502-902 | PATCH | 12 mg | TRANSDERMAL | NDA | 31 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2918 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-176 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
SELEGILINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-0055 | CAPSULE | 5 mg | ORAL | ANDA | 13 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-3438 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
SELEGILINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2649 | CAPSULE | 5 mg | ORAL | ANDA | 19 sections |
Selegiline Hydrochloride | Human Prescription Drug Label | 1 | 70954-504 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71205-888 | CAPSULE | 5 mg | ORAL | ANDA | 19 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71205-888 | CAPSULE | 5 mg | ORAL | ANDA | 19 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72319-006 | TABLET | 5 mg | ORAL | ANDA | 15 sections |